Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Atara Biotherapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 41 | 1 | 33 | −7 |
| Shares | 2.05M | 225.9K | 2.56M | +740.5K (+40.6%) |
| Value | $37.1M | $4.09M | $12.1M | −$20.8M (−63.2%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 700,000 | $3.31M | 0.01% |
| Vanguard Capital Management LLC | 217,862 | $1.03M | 0.00% |
| Millennium Management LLC | 47,689 | $225.6K | 0.00% |
| Vanguard Fiduciary Trust Co | 33,621 | $159.0K | 0.00% |
| Vanguard Global Advisers, LLC | 1,456 | $6.89K | 0.00% |
| PlanVest Financial, Inc | 28 | $132 | 0.00% |
| Citigroup Inc | 1 | $5 | 0.00% |
Sold out (14)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Marshall Wace, LLP | 148,632 | $2.69M |
| Globeflex Capital L P | 77,224 | $1.40M |
| Renaissance Technologies LLC | 30,040 | $543.4K |
| Cambridge Investment Research Advisors, Inc. | 22,864 | $414.0K |
| Quadrature Capital Ltd | 20,321 | $367.6K |
| Citadel Advisors LLC | 15,577 | $281.8K |
| Susquehanna International Group, LLP | 14,018 | $253.6K |
| Walleye Capital LLC | 12,169 | $220.1K |
| Connor, Clark & Lunn Investment Management Ltd. | 10,446 | $189.0K |
| Bank of America Corp | 10,387 | $187.9K |
| Dimensional Fund Advisors LP | 10,028 | $181.4K |
| Tower Research Capital LLC (TRC) | 1,737 | $31.4K |
| Private Wealth Asset Management, LLC | 900 | $16.3K |
| Federated Hermes, Inc. | 130 | $2.35K |
Not filed for Q1 2026 yet (1)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 225,940 | $4.09M |